Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Clinical Chemistry

Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMatthew LeeThe University of Texas Southwestern Medical CenterJSJeffrey A. SoRelleSouthwestern Medical CenterAEArun Everest-DassGriffith University

Discussion

Loading...

Member takes

Implication

Review highlights established and investigational biomarkers for immune checkpoint inhibitors, suggesting innovations for better patient outcomes.

Key Points

  • This review addresses the need for effective predictive biomarkers to optimize the use of immune checkpoint inhibitors in cancer therapy.
  • Review of established and investigational biomarkers for immune checkpoint inhibitors.
  • Analysis of biology, assay modalities, and limitations of current biomarkers.
  • Discussion on composite models that integrate various biomarker signals.
  • Established biomarkers like PD-L1, TMB, and microsatellite instability are used in practice but have limitations.
  • Investigational biomarkers across multiple domains show potential for enhancing patient selection.
  • Proposed harmonization and validation of assays may enhance biomarker efficacy for personalized therapies.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a363147db0793dc1a5382b1https://doi.org/10.1093/clinchem/hvag062
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB2023 · 23 citations
  2. 2Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer2015 · 6,324 citations
  3. 3The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients2018 · 3,140 citations